The U.S. Food and Drug Administration revised the emergency use authorization (EUA) for AstraZeneca’s Evusheld to a higher dose to be effective in the prevention of COVID-19. 

COVID vaccine, AstraZeneca

A large study into rare blood clots linked with AstraZeneca’s COVID-19 vaccine found between just one and three cases per million, and only after the first dose, shedding fresh light on the side effects from the shot.

AstraZeneca

AstraZeneca said the company’s Enhertu cancer drug has been shown to significantly help women suffering from a type of breast cancer that leaves them with poor treatment options, opening the door to a much larger potential patient group.

With the Omicron surge waning – at least in the United States – there is speculation that the COVID-19 pandemic may be in its end stages, although some experts warn that this could be premature.

The U.S. Commerce Department added 33 Chinese entities to an “unverified list,” requiring U.S. exporters to undergo more procedures before shipping goods to the companies. WuXi Biologics was amongst those on the list, with the United States stating that it was unable to verify the legitimacy and reliability of the company’s use of U.S. exports. 

AstraZeneca’s Chinese operation is under intense scrutiny by the National Healthcare Security Administration of China over concerns about suspected medical insurance fraud perpetrated by company employees.

When AstraZeneca presented positive updated results from the Phase III ASCEND study of CALQUENCE (acalabrutinib), it marked an important milestone for the company as the jewel in the crown of what management hopes will become a significant hematology portfolio. That study was significant for patients, too, because it represented a landmark 36 months of follow-up in chronic lymphocytic leukemia (CLL), which is considered an incurable disease.

A third booster dose of a COVID-19 vaccine made by AstraZeneca, Pfizer-BioNTech or Johnson & Johnson increases antibody levels significantly in those who have previously received two doses of Sinovac’s CoronaVac shot, a study has found.

AstraZeneca reported what the company called “unprecedented survival,” in the HIMALAYA Phase III trial using a single priming dose of tremelimumab added to the anti-PD-L1 checkpoint inhibitor Imfinzi (durvalumab) compared to Bayer’s Nexavar (sorafenib) as a first-line treatment for unresectable hepatocellular carcinoma (HCC) patients who had not received previous systemic therapy and as a result, were not eligible for localized treatment.

Scorpion Therapeutics and AstraZeneca partnered to develop precision medicines against previously hard-to-target cancer proteins.